Senseonics Holdings Inc (SENS) Sees Significant Increase in Short Interest

Senseonics Holdings Inc (NYSEAMERICAN:SENS) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 4,088,887 shares, a growth of 6.2% from the November 30th total of 3,851,216 shares. Currently, 8.4% of the shares of the company are short sold. Based on an average daily volume of 371,087 shares, the short-interest ratio is currently 11.0 days.

In related news, COO Mukul Jain sold 11,885 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $3.25, for a total value of $38,626.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Peter J. Barris sold 139,645 shares of the firm’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $2.63, for a total transaction of $367,266.35. The disclosure for this sale can be found here. Company insiders own 34.10% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. bought a new position in shares of Senseonics during the second quarter worth approximately $276,000. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Senseonics by 221.4% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 263,562 shares of the company’s stock worth $474,000 after purchasing an additional 181,562 shares during the period. Citadel Advisors LLC bought a new position in shares of Senseonics during the third quarter worth approximately $194,000. Susquehanna International Group LLP bought a new position in Senseonics in the second quarter valued at approximately $155,000. Finally, Renaissance Technologies LLC bought a new position in Senseonics in the first quarter valued at approximately $111,000. 30.66% of the stock is currently owned by institutional investors.

Senseonics (NYSEAMERICAN:SENS) traded up $0.15 during trading on Wednesday, reaching $2.75. 511,294 shares of the company’s stock traded hands, compared to its average volume of 465,598. The company has a market cap of $367.87 and a PE ratio of -5.50. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.81 and a current ratio of 2.93. Senseonics has a 52-week low of $1.26 and a 52-week high of $3.67.

Senseonics (NYSEAMERICAN:SENS) last released its quarterly earnings results on Tuesday, October 31st. The company reported ($0.13) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). Senseonics had a negative net margin of 828.76% and a negative return on equity of 406.72%. The firm had revenue of $2.10 million for the quarter, compared to analysts’ expectations of $1.51 million. Senseonics’s quarterly revenue was up 425.0% on a year-over-year basis. equities analysts forecast that Senseonics will post -0.54 EPS for the current year.

Separately, Canaccord Genuity reissued a “buy” rating on shares of Senseonics in a report on Wednesday, November 1st.

ILLEGAL ACTIVITY NOTICE: “Senseonics Holdings Inc (SENS) Sees Significant Increase in Short Interest” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/27/senseonics-holdings-inc-sens-sees-significant-increase-in-short-interest.html.

Senseonics Company Profile

Senseonics Holdings, Inc is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply